Headache for Zosano as FDA turns down migraine patch
pharmaphorum
OCTOBER 21, 2020
Zosano Pharma has been hit by an FDA rejection of its marketing application for migraine drug Qtrypta, asking for new bioequivalence data. Qtrypta is Zosano’s lead product candidate, but the company is also working on a follow-up in phase 2/3 for cluster headache.
Let's personalize your content